CannaTech

DECEMBER 15, 2019

Can you imagine a pain doctor giving a patient such alarming advice? Of course not, this would never happen in the majority of our healthcare system, but with cannabis, it’s different, the patient must figure it out on their own. The light switch has already turned on for many patients. It is 100% patient driven.

Microdosing 52

Microdosing Education Patients Medicine 52

Cannabis Law Report

JUNE 23, 2021

But despite the lengthy race to FDA approval in the US and the slow stream of Section 56 exemptions in Canada (currently fewer than 100 patients/physicians in Canada are granted access to psilocybin), revenue-generating opportunities and a sector are still emerging. though acknowledges the direct-to-consumer path is a long-term play.

Microdosing 59

Microdosing Business Research and Development Access 59

Veriheal

SEPTEMBER 2, 2021

Note: Veriheal does not support illegally consuming therapeutic substances like psilocybin magic mushrooms but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Researching Psilocybin for Migraines.

Treatment 98

Treatment Microdosing Therapy Patients 98

Cannabis Law Report

SEPTEMBER 10, 2019

Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression. Psychedelic Research News.

Research and Development 45

Research and Development Microdosing Clinical Trials Decriminalization 45

Cannabis Law Report

MARCH 3, 2022

The team at Microdose, the world’s biggest medical psychedelic conference , said the country’s move to permit Med Plant Science Ltd to produce psychedelic compounds makes it the first country to legalize all psychedelic medicine. . Vincent and the Grenadines Legalizes Psychedelic Medicine. COMPANY PRESS RELEASE.

Research and Development 52

Research and Development Medicine Clinical Trials Microdosing 52

Cannabis Law Report

NOVEMBER 24, 2019

Future studies will explore psilocybin’s effectiveness as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa, and alcohol use in people with major depression. Participate in Our Studies.

Therapy 59

Therapy Treatment Medicine Clinical Trials 59

The Cannigma

FEBRUARY 3, 2022

of babies, to doing robotic surgery, and now, helping geriatric patients navigate cannabis medicine. We find out how women and other estrogen-predominant people react differently to cannabis than men and those with more testosterone, and why microdosing is far more effective for the former.

Wellness and Beauty 109

Wellness and Beauty Patients Medicine Cannabis 109

Cannabis Law Report

JUNE 4, 2021

Andrew is a supporter of legalizing psychedelic drugs and has been vocal about his intentions if he were to assume a government office. Sessa is also the Chief Medical Officer of Awakn Life Sciences, and has been a part of scientific and clinical studies administering LSD, psilocybin, ketamine, MDMA and DMT to patients and volunteers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51